Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


3SBio Discontinues NuLeusin; Sinovac To Benefit From Government Vaccine Supply Plan: China Earnings Roundup (Part 3)

This article was originally published in PharmAsia News

Executive Summary

China's generic pharma companies suffered a slowdown in Q3, but biotech companies saw healthy growth.

You may also be interested in...

From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step

SHANGHAI - 3SBio Inc.'s success with a biosimilar of Amgen Inc.'s erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government

With Limits Created By China's New Pharmacopoeia, What's Next For Vaccine Manufacturers?

SHANGHAI - China is expected to be the world's largest vaccine market by 2020, and every vaccine maker is trying to increase their presence to gain market share. However, the new Chinese Pharmacopoeia might put these efforts to an end and almost all vaccines from multinational companies may have to withdraw from China if they fail to comply with new standards

China's State FDA Steps Up Transparency With First Annual Review Of Drug Approval Process, Outcome

BEIJING - In a step toward lifting a longstanding veil on the drug review process in China, the State FDA has for the first time issued a public outline of the range and types of medicines approved by regulators last year


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts